Global Metabolomics Market

1 INTRODUCTION OF GLOBAL METABOLOMICSMARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL METABOLOMICSMARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework
5 GLOBAL METABOLOMICS MARKET, BY INDICATION
5.1 Cancer
5.2 Cardiovascular Disorders
5.3 Neurological Disorders
5.4 Inborn Errors of Metabolism
5.5 Other Indications

6 GLOBAL METABOLOMICS MARKET, BY APPLICATION
6.1 Biomarker Discovery
6.2 Drug Discovery
6.3 Toxicology Testing
6.4 Nutrigenomics
6.5 Functional Genomics
6.6 Personalized Medicine
6.7 Other Applications

7 GLOBAL METABOLOMICS MARKET, BY PRODUCT AND SERVICES
7.1 Metabolomics Instruments
7.1.1 Separation Tools
7.1.1.1 High-Performance Liquid Chromatography
7.1.1.2 Gas Chromatography
7.1.1.3 Ultra-Performance Liquid Chromatography
7.1.1.4 Capillary Electrophoresis
7.1.2 Detection Tools
7.1.2.1 Mass Spectrometry
7.1.2.2 Nuclear Magnetic Resonance Spectroscopy
7.1.2.3 Surface-Based Mass Analysis
7.1.3 Metabolomics Bioinformatics tools and services
7.1.4 Bioinformatics Tools & Databases
7.1.5 Bioinformatics Services
8 GLOBAL METABOLOMICSMARKET, BY GEOGRAPHY
8.1 Overview
8.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.2.1 U.S.
8.2.2 Canada
8.2.3 Mexico
8.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
8.3.1 Germany
8.3.2 U.K.
8.3.3 France
8.3.4 Rest of Europe
8.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Rest of Asia Pacific
8.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
8.5.1 Brazil
8.5.2 Argentina
8.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 - 2025

9 GLOBAL METABOLOMICSMARKETCOMPETITIVE LANDSCAPE
9.1 Overview
9.2 Company Market Share
9.3 Vendor Landscape
9.4 Key Development Strategies

10 COMPANY PROFILES
10.1 Thermo Fisher Scientific Inc.
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments

10.2 Agilent Technologies, Inc.
10.2.1 Overview
10.2.2 Financial Performance
10.2.3 Product Outlook
10.2.4 Key Developments

10.3 Waters Corporation
10.3.1 Overview
10.3.2 Financial Performance
10.3.3 Product Outlook
10.3.4 Key Developments

10.4 Danaher Corporation
10.4.1 Overview
10.4.2 Financial Performance
10.4.3 Product Outlook
10.4.4 Key Developments

10.5 Shimadzu Corporation
10.5.1 Overview
10.5.2 Financial Performance
10.5.3 Product Outlook
10.5.4 Key Developments

10.6 Biocrates Life Sciences AG
10.6.1 Overview
10.6.2 Financial Performance
10.6.3 Product Outlook
10.6.4 Key Developments

10.7 Bio-Rad Laboratories, Inc.
10.7.1 Overview
10.7.2 Financial Performance
10.7.3 Product Outlook
10.7.4 Key Developments

10.8 Bruker Corporation
10.8.1 Overview
10.8.2 Financial Performance
10.8.3 Product Outlook
10.8.4 Key Developments

10.9 Human Metabolome Technologies, Inc.
10.9.1 Overview
10.9.2 Financial Performance
10.9.3 Product Outlook
10.9.4 Key Developments

10.10 Leco Corporation
10.10.1 Overview
10.10.2 Financial Performance
10.10.3 Product Outlook
10.10.4 Key Developments

10.11 Metabolon, Inc.
10.11.1 Overview
10.11.2 Financial Performance
10.11.3 Product Outlook
10.11.4 Key Developments

11 Appendix
11.1 Related Reports